Browse diseases

…stomized build to support biomarker discovery for patients with melanoma. Two examples where this data structure was used to support bio…

…stently observed across multiple institutions for patients with melanoma. This now-approved strategy approaches 35% in recent studies fr…

…patient presented with an extensive oncologic history including osteogenic sarcoma, melanoma and pulmonary neoplasm, suggesting that his cardiac m…

…iltrating lymphocytes (TIL) has demonstrated durable benefit in melanoma, but its role in pancreatic ductal adenocarcinoma (PDAC) remain…

…ars-of-age with histologically confirmed stage II–IV resectable cSCC (without M1; head/neck tumor staging per AJCC 8th ed; other tum…

…zumab generated clinically meaningful anti-tumor efficacy in 2L CPI-refractory melanoma patients, indicating the potential to overcome resistance to ch…

…ng lymphocytes (TIL) has shown efficacy in malignancies such as melanoma, and preclinical data support this approach in bladder cancer. …

…-infiltrating lymphocytes (TIL) has shown promising efficacy in melanoma, however limited response has been seen in other solid tumor ty…

…ma (51.8%; n=73), non-small cell lung cancer (16.3%; n=23), and renal cell carcinoma (6.4%; n=9). Our result showed a significant difference between…

… that the IL7 polymorphism rs16906115 may increase irAE risk in melanoma and renal cell carcinoma (RCC) patients treated with ICIs.Metho…

…anuary 2003 to September 2022, 453 patients were diagnosed with malignant melanoma and were treated with immunotherapy or targeted therapy. The me…

…cy (n=13,497, 40.8%), followed by genitourinary (n=5,449, 16%), melanoma (n=4,442, 13%), gastrointestinal (n=4,103, 12%), and breast (n=…